Progenics Pharmaceuticals Inc. (PGNX) Shares Down 3.9%
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)’s share price traded down 3.9% during trading on Wednesday . The company traded as low as $6.18 and last traded at $6.19, with a volume of 715,419 shares traded. The stock had previously closed at $6.44.
A number of equities analysts recently commented on the company. Brean Capital restated a “buy” rating and issued a $14.00 price objective on shares of Progenics Pharmaceuticals in a report on Friday, May 6th. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 6th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Progenics Pharmaceuticals in a report on Friday, July 22nd. Jefferies Group reiterated a “buy” rating on shares of Progenics Pharmaceuticals in a report on Friday, June 10th. Finally, BTIG Research reiterated a “buy” rating and set a $9.00 price target on shares of Progenics Pharmaceuticals in a report on Wednesday, July 20th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.95.
The firm’s 50 day moving average is $6.19 and its 200-day moving average is $5.11. The firm’s market capitalization is $439.51 million.
Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its earnings results on Thursday, August 4th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. The business had revenue of $8.50 million for the quarter, compared to analyst estimates of $6.33 million. During the same period in the previous year, the firm posted ($0.17) earnings per share. The firm’s revenue was up 337.6% compared to the same quarter last year. Equities analysts anticipate that Progenics Pharmaceuticals Inc. will post $0.13 EPS for the current fiscal year.
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.